BKM120 (NVP-BKM120, Buparlisib)

Catalog No.S2247

BKM120 (NVP-BKM120, Buparlisib) Chemical Structure

Molecular Weight(MW): 410.39

BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 34 Publications

3 Customer Reviews

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

    One customer. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

  • Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. BKM120 (NVP-BKM120, Buparlisib) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MoXJR5l1d3SxeHnjJGF{e2G7 MmrTO|IhcA>? NIT1WHFFVVOR NV3BNow{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> NFjnW4EzPDlyMEK2Oi=>
DU145 MnX1R5l1d3SxeHnjJGF{e2G7 MnjjO|IhcA>? MVvEUXNQ Mk\BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP NEmxUHYzPDlyMEK2Oi=>
A2780 NG\SeZlEgXSxdH;4bYMhSXO|YYm= MmmzO|IhcA>? M3\hO2ROW09? MoLSR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlM2KM7:TR?= MnnCNlQ6ODB{Nk[=
U87MG M3fnW2N6fG:2b4jpZ{BCe3OjeR?= MmnhO|IhcA>? M1OyV2ROW09? NYP1SHVOS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjl6IN88US=> M3HYO|I1QTByMk[2
A2780 MkXYSpVv[3Srb36gRZN{[Xl? NFv1bmUyKGh? M1LTe2ROW09? M4DJT2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh|ryP MmXoNlQ6ODB{Nk[=
DU145 NFy2O|FHfW6ldHnvckBCe3OjeR?= Mlu2NUBp NH;0fmhFVVOR MmOxTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? M1TrUlI1QTByMk[2
A2780 NFfRfWVHfW6ldHnvckBCe3OjeR?= NXrkZXM4OSCq NIPOSmxFVVOR NFzzRlJKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR|UxKG:oIECuNFc1KM7:TR?= NVPCc41ZOjR7MECyOlY>
MCF7 Mn;hSpVv[3Srb36gRZN{[Xl? MoDLNUBp MWjEUXNQ M1TlW2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? NGHSVFAzPDlyMEK2Oi=>
U87MG MV\GeY5kfGmxbjDBd5NigQ>? M3:0bVEhcA>? MmHiSG1UVw>? MmfHTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiRVO1NEBw\iByLkGzJO69VQ>? NW[2O|FZOjR7MECyOlY>
A2780 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnse2c4PzJiaB?= NInRZ25FVVOR NETsXodGSzVyPUCuOVIh|ryP MXeyOFkxODJ4Nh?=
SKMES-1 NG\1N2FEgXSxdH;4bYMhSXO|YYm= Mo\rNUDPxE1? Mkj6O|IhcA>? NH[5S45KdmS3Y3XzJINmdGxiZHXheIg> MkTYNlYxOTN|MUi=
H596 NIr3OmdHfW6ldHnvckBCe3OjeR?= NVK1[4prOSEQvF2= M4O2ZmlueGGrcoOgZ4VtdCCvaXfyZZRqd25? MoHINlYxOTN|MUi=
HCC2450 NI\wRmxHfW6ldHnvckBCe3OjeR?= NUDp[o5iOSEQvF2= MXjJcZBicXK|IHPlcIwhcW64YYPpc44> NWTPUoJYOjZyMUOzNVg>
A549 NHLvTm5HfW6ldHnvckBCe3OjeR?= NEjTRVA2ODBibl2= MlHjOFghcA>? MXXEUXNQ M{XuRmlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w NH7IPFkzPTl|N{K5PS=>
A549 M{iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3he25YOSEQvF2= NFvaN3k4OiCq MVfEUXNQ MYLJcohq[mm2czDj[YxtKGe{b4f0bC=> M{fK[VI2QTN5Mkm5
H522 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vo[FEh|ryP M4r0d|czKGh? MWDEUXNQ MmXYTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NYrWR4M4OjV7M{eyPVk>
LNCaP MWjGeY5kfGmxbjDBd5NigQ>? MVqxJO69VQ>? MmrqV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? MkXqNlU{PjB5OUm=
LNCaP95 MVPGeY5kfGmxbjDBd5NigQ>? MkjwNUDPxE1? NV\ERoEyW3WycILld5NmeyCyLVHLWEBt\X[nbIO= NWXPcVdqOjV|NkC3PVk>
HCT-15 M2fCU2Fxd3Sxc3nzJGF{e2G7 M1fEb|ExKM7:TR?= M3HRVlQ5KGh? Mof2SG1UVw>? NH\kb|VKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M{f5[FI2OTV{MkS1
HCT-116 NGDGS3BCeG:2b4Ppd{BCe3OjeR?= NFHFcngyOCEQvF2= MXK0PEBp NIPjOmhFVVOR NEiyUnlKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= NHjCcJAzPTF3MkK0OS=>
NCI-H460 NEn3dodCeG:2b4Ppd{BCe3OjeR?= M2rVUVExKM7:TR?= NF3xRWY1QCCq MXPEUXNQ NUnzOWlkUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> MXWyOVE2OjJ2NR?=
SKOV-3 NWX5dYY2SXCxdH;zbZMhSXO|YYm= NH7EdYoyOCEQvF2= MWe0PEBp Mm\FSG1UVw>? NIi5SVZKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MV6yOVE2OjJ2NR?=
BSY-1 NHvvZ|VCeG:2b4Ppd{BCe3OjeR?= NYn0XZBTOTBizszN NXX2S4ExPDhiaB?= Mn;BSG1UVw>? NInQPY9KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M33reFI2OTV{MkS1
MKN-1 NFPlUmdCeG:2b4Ppd{BCe3OjeR?= NVqwSo5pOTBizszN MWS0PEBp MXrEUXNQ MoDTTY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NXXaTW9zOjVzNUKyOFU>
NCI-H522 NYSweppySXCxdH;zbZMhSXO|YYm= MVyxNEDPxE1? NXnTU2d4PDhiaB?= Mo\FSG1UVw>? MmThTY5lfWOnczDhdI9xfG:|aYO= MUiyOVE2OjJ2NR?=
OVCAR-3 M{SwNWFxd3Sxc3nzJGF{e2G7 M1rkSFExKM7:TR?= NVTyfWZCPDhiaB?= MnLPSG1UVw>? NGPUNm1KdmS3Y3XzJIFxd3C2b4Ppdy=> NUTaU21[OjVzNUKyOFU>
HBC-5 M{SwVmFxd3Sxc3nzJGF{e2G7 NUjxfXpOOTBizszN M16yZVQ5KGh? MnzxSG1UVw>? MkK1TY5lfWOnczDhdI9xfG:|aYO= NVrXRox{OjVzNUKyOFU>
RXF-631L Mof0RZBwfG:|aYOgRZN{[Xl? NEXtNmoyOCEQvF2= MXK0PEBp NX;BVpVUTE2VTx?= MV\JcoR2[2W|IHHwc5B1d3Orcx?= Mkf3NlUyPTJ{NEW=
MKN-45 M3fxdWFxd3Sxc3nzJGF{e2G7 M{LHelExKM7:TR?= MV20PEBp NEHMUnBFVVOR NWjjPYxFUW6mdXPld{BieG:ydH;zbZM> M{fZOFI2OTV{MkS1
BON-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vqVlUxOCCwTR?= NEjaOnEyOCCm NGTVVXlFVVOR NIj0dJJKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIruZnAzPTB{NkK5Ni=>
BON-1 NFjDNnBHfW6ldHnvckBCe3OjeR?= M3PBS|UxOCCwTR?= NYfONFNjPCCq Ml3MSG1UVw>? M1\4XmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= MlnlNlUxOjZ{OUK=
QGP-1 M3nVRWZ2dmO2aX;uJGF{e2G7 NYT1NYt4PTByIH7N NF6wZok1KGh? M1Ttc2ROW09? MknHTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NX7ENmJIOjVyMk[yPVI>
Huh7 NWjCdFNqTnWwY4Tpc44hSXO|YYm= MXuxJO69VQ>? MlL1NUBp NUjjOJVDTE2VTx?= M2jlc2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgV4VzPDd2 MUiyOVAxPDRyMx?=
BNL NGfW[25HfW6ldHnvckBCe3OjeR?= M36ycFEh|ryP MWixJIg> Mm\sSG1UVw>? M2PKOmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? MonWNlUxODR2MEO=
MDA-MB-175 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\KNUDPxE1? MnHiOUBl MkfUSG1UVw>? M3nDeWlEPTB:MTFOwG0> M4WzTVI1QDd7N{m2
MDA-MB-134 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTYNUDPxE1? NH[0RWM2KGR? NVXW[2h1TE2VTx?= NGKwfIxKSzVyPEGg{txO MViyOFg4QTd7Nh?=
HCC1500 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETXencyKM7:TR?= M4Hy[lUh\A>? MYfEUXNQ NGTm[JNKSzVyPEGg{txO M{HSUlI1QDd7N{m2
EFM-19 NEn2dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7o[IJpOSEQvF2= MX21JIQ> NFfVcoZFVVOR MlzwTWM2ODxzIN88US=> NUGyeIxbOjR6N{m3PVY>
ZR-75-30 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP2NUDPxE1? NXixcVlnPSCm Ml3HSG1UVw>? MmPGTWM2ODxzIN88US=> NITpfJYzPDh5OUe5Oi=>
MDA-MB-361 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xJO69VQ>? NW\GXYdvPSCm NH3LcHBFVVOR MUDJR|UxRDFizszN M4fQbVI1QDd7N{m2
T-47D NXHkXo45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xJO69VQ>? MlLiOUBl MkjwSG1UVw>? MWTJR|UxRDFizszN NU[4bYxOOjR6N{m3PVY>
SK-BR-3 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TadFEh|ryP NHTXN2E2KGR? NHe1b5FFVVOR MX;JR|UxRDFizszN MVmyOFg4QTd7Nh?=
UACC-732 M3PjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xJO69VQ>? NEjD[Vc2KGR? M{X1TGROW09? NVPtSoV2UUN3MEyxJO69VQ>? NWW2bZl6OjR6N{m3PVY>
BT-474 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrmOWYyKM7:TR?= MXm1JIQ> MkfRSG1UVw>? NHS5RW9KSzVyPEGg{txO MlLJNlQ5Pzl5OU[=
HCC202 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWxJO69VQ>? NYftcIpRPSCm NEjVfGtFVVOR MnzZTWM2ODxzIN88US=> MX2yOFg4QTd7Nh?=
MCF7 M3vpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxJO69VQ>? NW\MT4lvPSCm MXrEUXNQ M1PGT2lEPTB:MTFOwG0> M3XJbVI1QDd7N{m2
MDA-MB-415 NFPjdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PGfFEh|ryP NVfQW49wPSCm MXjEUXNQ NHPxdXNKSzVyPEGg{txO NWHGfpJOOjR6N{m3PVY>
MDA-MB-453 M{Lvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12yZlEh|ryP M17vTlUh\A>? NXO3[2E{TE2VTx?= MWfJR|UxRDFizszN NYHzVHdEOjR6N{m3PVY>
ZR-75-1 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\HSFEh|ryP NVXXTZdMPSCm NXf0RpZSTE2VTx?= NGjQUlRKSzVyPEGg{txO M3z6O|I1QDd7N{m2
HCC38 M2DBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxJO69VQ>? NGHY[ok2KGR? MmTuSG1UVw>? NEHrcGxKSzVyPEGg{txO MnP5NlQ5Pzl5OU[=
HCC1419 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixJO69VQ>? MV21JIQ> M{fwbGROW09? MofCTWM2ODxzIN88US=> M1K0R|I1QDd7N{m2
UACC-812 NVK2VGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfhS3I5OSEQvF2= M1nHe|Uh\A>? M2XzbWROW09? NFfCSYZKSzVyPEGg{txO NFHobWszPDh5OUe5Oi=>
HCC1187 NHLwc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3xVJEyKM7:TR?= MYK1JIQ> Mo\5SG1UVw>? NHy3N4VKSzVyPEGg{txO MY[yOFg4QTd7Nh?=
KPL-1 M1\V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7KNUDPxE1? M2mxWFUh\A>? M1;nR2ROW09? MYDJR|UxRDFizszN NVnSXpN3OjR6N{m3PVY>
SUM-225 NXzVdlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO5OFUyKM7:TR?= M3ziUlUh\A>? MVjEUXNQ MWrJR|UxRDFizszN NFHoWVAzPDh5OUe5Oi=>
EFM-192A NYL4[HNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz6NUDPxE1? MnSyOUBl M1zvWGROW09? MlTPTWM2ODxzIN88US=> M4jITFI1QDd7N{m2
JIMT-1 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLENHMyKM7:TR?= MWe1JIQ> M3HFOmROW09? NHexPJZKSzVyPEGg{txO NEWwOVQzPDh5OUe5Oi=>
HCC1143 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jCVlEh|ryP MorwOUBl NITTT|JFVVOR MlfwTWM2ODxzIN88US=> MX2yOFg4QTd7Nh?=
HCC2218 M1\NNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\GfI5iOSEQvF2= MorMOUBl M4CxUWROW09? MkL4TWM2ODxzIN88US=> MnfwNlQ5Pzl5OU[=
MDA-MB-468 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWxJO69VQ>? M4fYcFUh\A>? MkfOSG1UVw>? NHzOSlhKSzVyPEGg{txO M1Tab|I1QDd7N{m2
BT-20 NXH1dY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;qWVEh|ryP M17FSVUh\A>? M4GzVWROW09? MVHJR|UxRDFizszN MUKyOFg4QTd7Nh?=
MDA-MB-435 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xJO69VQ>? MUe1JIQ> MUfEUXNQ Mo\ITWM2ODxzIN88US=> NGqwcnkzPDh5OUe5Oi=>
BT-549 M1PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxJO69VQ>? NXzTd|ZxPSCm MlTUSG1UVw>? NHvXdXZKSzVyPEGg{txO MoP2NlQ5Pzl5OU[=
HCC1806 NWTWOllDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJelJJOSEQvF2= Ml7FOUBl Mn;DSG1UVw>? NInVeIhKSzVyPEGg{txO MV:yOFg4QTd7Nh?=
HCC1937 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xJO69VQ>? Mo[1OUBl MkfmSG1UVw>? M4ixXWlEPTB:MTFOwG0> NHr5VmwzPDh5OUe5Oi=>
Hs578T NEnxOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XKSFEh|ryP NWDKZVhrPSCm MYjEUXNQ M3;hSGlEPTB:MTFOwG0> MWSyOFg4QTd7Nh?=
LN18 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vTFIxKM7:TR?= NUXOcnBRPzJiaB?= M2fKbmROW09? M4Dme2lEPTB:NTFOwG0> Ml7aNlQ4PDFyN{S=
LN229 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:3NlAh|ryP M{DwblczKGh? Mn\DSG1UVw>? NF3tZpdKSzVyPEWg{txO NEf6UowzPDd2MUC3OC=>
LNZ308 NF3lTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofLNlAh|ryP MkfKO|IhcA>? MUjEUXNQ MULJR|UxRDVizszN MlXWNlQ4PDFyN{S=
T98G MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHraUIQzOCEQvF2= NF64U3c4OiCq NXW0VpptTE2VTx?= MVjJR|UxRDVizszN MXGyOFc1OTB5NB?=
U87 NWG1flQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Sc5dCOjBizszN MWC3NkBp MVvEUXNQ NGnzVYVKSzVyPEWg{txO NF63WIIzPDd2MUC3OC=>
LN18 NYnmT3V2TnWwY4Tpc44hSXO|YYm= NHLhPYY2KM7:TR?= MXuyOEBp MlrjSG1UVw>? NHXjfWlKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW MnTSNlQ4PDFyN{S=
LNZ308 NF;6[VlHfW6ldHnvckBCe3OjeR?= MUG1JO69VQ>? MWOyOEBp Mn71SG1UVw>? M1TkWmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? NYnvSHJEOjR5NEGwO|Q>
Saos-2 NVrNeGN1TnWwY4Tpc44hSXO|YYm= M3;UclUxKM7:TR?= M3LGPVQ5KGh? M1;ofmlvcGmkaYTzJINmdGxiaX72ZZNqd25? M{i1VVI1PzJ5Nk[w
MG-63 M1uxWWZ2dmO2aX;uJGF{e2G7 NHWxdII2OCEQvF2= M1O5cVQ5KGh? NWXxe3k5UW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MUKyOFczPzZ4MB?=
SJSA-1 MWrGeY5kfGmxbjDBd5NigQ>? NF\xNpM2OCEQvF2= NUDtWIk6PDhiaB?= M3z0O2lvcGmkaYTzJINmdGxiaX72ZZNqd25? NVrRdFhmOjR5Mke2OlA>
Saos-2 NVLJOYU2TnWwY4Tpc44hSXO|YYm= MmHCOVAh|ryP M{K1XVQ5KGh? NUD5Z2tZUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? NF7l[pAzPDd{N{[2NC=>
MG-63 MnLlSpVv[3Srb36gRZN{[Xl? MUS1NEDPxE1? MVe0PEBp NUS0OXZEUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MnS0NlQ4Ojd4NkC=
SJSA-1 NYTyXHZETnWwY4Tpc44hSXO|YYm= NISyc3E2OCEQvF2= MmDoOFghcA>? M2nJdmlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MoX6NlQ4Ojd4NkC=
Saos-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD6c|dHPTBizszN MkCyOFghcA>? MVjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? Mo[4NlQ4Ojd4NkC=
MG-63 M1f0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rXXlUxKM7:TR?= NVnxcHpqPDhiaB?= NFqzcXhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mn3NNlQ4Ojd4NkC=
SJSA-1 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi1NEDPxE1? NU\ENphGPDhiaB?= NGK3d|VKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MX:yOFczPzZ4MB?=
FaDu MVnGeY5kfGmxbjDBd5NigQ>? MYO1JO69VQ>? NGWweVkzPCCq MYfEUXNQ MWjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= M13XcVI1PjNzMUS3
EMT6 M3z1c2Z2dmO2aX;uJGF{e2G7 MVu1JO69VQ>? NVjqNVhFOjRiaB?= NVfLTZc{TE2VTx?= NIXPSYpT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> M1\He|I1PjNzMUS3
HCT116 NIrPblZHfW6ldHnvckBCe3OjeR?= NF\rOHQ2KM7:TR?= NGH4bVUzPCCq NFnMUJZFVVOR NGfLZWFT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NVz6OFlYOjR4M{GxOFc>
U87 NEP1cZlHfW6ldHnvckBCe3OjeR?= NFrkV2o2KM7:TR?= Mlz0NlQhcA>? NWXxWIJmTE2VTx?= NXHjXYtmWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NFHQfJkzPDZ|MUG0Oy=>
GBM MlXrRZBweHSxc3nzJGF{e2G7 NWDEbmNVOs7:TR?= MkXyOFhp NEnXcFhFVVOR MYLpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 MlLoNlQ2ODB2OUK=
BON MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXnWI1kOS13zszN NFPJT3k4Omh? M{fZV4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M{C1elI1PDR|NUKz
BON M4fFUmFxd3C2b4Ppd{BCe3OjeR?= MmfSNU02|ryP NXriO5ZvOjSq M1TmNYlv[3KnYYPld{BieG:ydH;zbZM> NVL0WoJPOjR2NEO1NlM>
H1975 NXHHb|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnkd5VDOC5|LUmuOu69VQ>? NH3RXmQ4Omh? Moi0SG1UVw>? M4D5WmlEPTB;MT6zPFXPxE1? M1O3O|I1OzN5OES2
H1975 M3z3U2Fxd3C2b4Ppd{BCe3OjeR?= NETpc|Mz|ryP MWGyOIg> M1nsW2ROW09? M37OOolv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 M17rcFI1OzN5OES2
T-ALL MoHJRZBweHSxc3nzJGF{e2G7 M3GzXoJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NGnVVJYzPCCxcjC0PIg> M{DHcWROW09? MWXh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= NEHadG4zPDNzMEezOi=>
BCR-ABL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2U4hrOC5{NT2xNO69VQ>? NGDOZ4U1\A>? NEnq[2F{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w MmfwNlQzPDR4MUK=
LC-1/SQSF M1OzTGZ2dmO2aX;uJGF{e2G7 Moi4N:69VQ>? MnKwNlRp MU\EUXNQ NH;KdmJl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> M3nXWVI{QThyMEmz
Primary CLL cells Ml7xRZBweHSxc3nzJGF{e2G7 MXSxMVEx|ryP MXm0PIg> NXmwPZV[cW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>? M1TQV|I{QDVyOEC3
Primary CLL cells MUXLbY5ie2ViQYPzZZk> NUfvN5U4Os7:TR?= NWjONIN[OzCvaX6= M{\0ZoRm[3KnYYPl[EBRUTONIHHjeIl3cXS7 MWCyN|g2ODhyNx?=
Primary CLL cells M3r3bmN6fG:2b4jpZ{BCe3OjeR?= M{fKXlLPxE1? M2S0TFI1cA>? M1jpOYlv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm= NVnPUlBGOjN6NUC4NFc>
human NSCLC cell lines NFzGU45CeG:ydH;zbZMhSXO|YYm= Mm\qNE4yOjVvNN88US=> Moj5NlRp NXf3VoVjTE2VTx?= NUnUd5VwUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> Ml;QNlM2PjJ2N{K=
human HCC cell lines NEG1V3NE\WyuII\pZYJqdGm2eTDhd5NigQ>? NFOyOZMxNjByNT2x{txO MYG0PIg> MV7JR|UxRTIQvF2= MX2yN|Q5QTl7OR?=
Huh7 NVrlTYh4U2mwYYPlJGF{e2G7 MX[x{txO M4n1cFQ5cA>? M1L3cJNq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> Mme3NlM1QDl7OUm=
SK-HEP1 M1fKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxMVIx|ryP Mn34O|Jp MnPVSG1UVw>? NEXJSHlKSzVy78{cNe69VQ>? MWeyN|Q4QTF|Nh?=
786-0 M3nWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HINlEuOjEQvF2= M3nIbFczcA>? MnLQSG1UVw>? MoTuTWM2OO,:nEJOwG0> NEPSS2gzOzR5OUGzOi=>
JVM2 NIDidmREgXSxdH;4bYNqfHliYYPzZZk> NV;Gc25oOC5{LUKw{txO M4LCRVczcA>? NGWwOXRFVVOR M4fucGlEPTB;MD65{txO MWqyN|I{QDZ|OR?=
EHEB M4TvdmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3T1flAvOi1{MN88US=> MYW3Nog> M3fveWROW09? Ml72TWM2OD1yLkhOwG0> NIX0V4czOzJ|OE[zPS=>
MEC2 M2PvfmN6fG:2b4jpZ4l1gSCjc4PhfS=> MnvBNE4zNTJyzszN NIPHZpI4Omh? Ml60SG1UVw>? MVPJR|UxRTBwN988US=> MXqyN|I{QDZ|OR?=
primary B-CLL lymphocytes MkLQRZBweHSxc3nzJGF{e2G7 NWnCZXF4UUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= NIDESW0zPGh? MXPEUXNQ NFnvclNKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ MkfXNlMzOzh4M{m=
primary B-CLL lymphocytes MnH1T4lv[XOnIFHzd4F6 NF71UWtKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n NWrrWVdPOjSq MoXxbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= MYKyN|I{QDZ|OR?=
human NSCLC Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrl[o9nOC53LUNOwG0> MXy3Nog> NIDWdlBKSzVyPUJOwG0> NWLQ[o9MOjJ5OEGzPVM>
human NSCLC NHfxUo1McW6jc3WgRZN{[Xl? MkDxNe69VQ>? MWOyOIg> NX;Q[4RycW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=> MV6yNlc5OTN7Mx?=
Y1 cell line M2LTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfEb|QxNjIQvF2vNe69VQ>? NWnsWlNIOjSq M4XzN2ROW09? NW\vSGhTcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= MXmyNlY6OjlyNB?=
PIK3CA-mutant MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTWRVBIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= NVviZol7PzKq NVLnc2RbT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= M3\We|IzPjV|OU[3
PIK3CA-mutant MCF7 M4HGZmtqdmG|ZTDBd5NigQ>? MmLNTWM2OD1zMUVCtVNvVQ>? MnHiO|Jp MU\JR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| MnT3NlI3PTN7Nke=
MCF7-myr-Akt MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfVSolIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= MmrNO|Jp M172OGdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P MnrnNlI3PTN7Nke=
colon cancer cell lines NH7kPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;XOlMxNTFyzszN Mmr3O|Jp NEHPe3ZFVVOR NX;WfYpoUUN3ME2x{txO NX20NZBkOjJ3NEO4OVc>
gastric cancer cell lines Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r2VFAuOTEQvF2= NGrqW|A4Omh? NWTBb|VbTE2VTx?= M2DqPWlEPTB;Mj21{txO NUnQPYk4OjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 Mn;CRZBweHSxc3nzJGF{e2G7 M4DmPFLPxE1? M2W3OVQ5cA>? NXXOZVVEe2irZoSgbY4hTzJicHjhd4U> Mm[0NlI2PDN6NUe=
HT-29 and HCT-116 MlPyR4F{eGG|ZTDhd5NigQ>? M12xPVXPxE1? MWqyOIg> MkfnbY5lfWOnczDjZZNx[XOnIHHjeIl3cXS7 NUn1OXJIOjJ3NEO4OVc>
MM cell lines NGHDRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNO69VQ>? NHnyfmUzPGh? MV;EUXNQ M4nzVmlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>? NE\0RVQzOjJyN{S4OS=>
ARP-1 NV61O4VKSXCxcITvd4l{KEG|c3H5 M2DGb|Ex|ryP MU[yOIg> MXzEUXNQ M4PF[Ilv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= MX2yNlIxPzR6NR?=
SNU-601 NGe0ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ESmg4Omh? Ml[5SG1UVw>? M2nFV2lEPTB;MD64NVbDuTBwME[z{txO MoP5NlIyPTl6MUS=
SNU-1 NGrSR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxcpI4Omh? NWK4fVc1TE2VTx?= MnvoTWM2OD1zLkC4NuKyOC5yMklOwG0> M4LIfVIzOTV7OEG0
SNU-668 NXfhO402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDKVm51PzKq MX7EUXNQ NIe1d4dKSzVyPUGuOVc6yrFyLkC3OO69VQ>? NHjPe3YzOjF3OUixOC=>
AGS MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCPWpCPzKq NVO0eJJ3TE2VTx?= MY\JR|UxRTFwN{G0xtExNjFzN988US=> MXmyNlE2QThzNB?=
SNU-216 NFTsVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjOXW84Omh? NULTVY54TE2VTx?= NGjXWlNKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? NUnwSlNqOjJzNUm4NVQ>
SNU-5 NH23dIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW3Nog> NEDTbGJFVVOR NV3qXVNJUUN3ME2xMlM2OcLzMD6wPVHPxE1? MX[yNlE2QThzNB?=
SNU-638 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn4O|Jp MWLEUXNQ Ml;JTWM2OD1{LkK4NuKyOC5yNUROwG0> NXLLNmdnOjJzNUm4NVQ>
SNU-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe0S5k4Omh? NVnFVm1iTE2VTx?= NI\nPZJKSzVyPUGuOVc{yrFyLkCwNe69VQ>? Mn;SNlIyPTl6MUS=
SNU-484 NVW5SXpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnuO|Jp Mn\ySG1UVw>? Mnm3TWM2OD1zLkeyPOKyOC5yNEZOwG0> NWHXfZJ7OjJzNUm4NVQ>
SNU-620 NVy4boQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T6UVczcA>? M1\1ZmROW09? MoPLTWM2OD1{LkmzPeKyOC5yMEJOwG0> MWOyNlE2QThzNB?=
SNU-719 NH;ONo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXlVJc4Omh? NIXXcWdFVVOR MoH6TWM2OD1|LkCzO:KyOC5yM{NOwG0> NV62OI9lOjJzNUm4NVQ>
glioma cell lines NH3GTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3Nog> NGq0Wm9KSzVyPUGtNu69VQ>? NXfHRplYOjJyNkWwPFA>
U87 NECxWXRCeG:ydH;zbZMhSXO|YYm= M131UlLPxE1? NETUPWk4Omh? NWTUR|BrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> MlfBNlIxPjVyOEC=

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water <1 mg/mL
In vivo 0.5% CMC Na 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) supplier | purchase BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) cost | BKM120 (NVP-BKM120, Buparlisib) manufacturer | order BKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID